Biota completes new flu trial
Thursday, 31 July, 2008
Biota Holdings [ASX: BTA] has completed the Phase II trials of its influenza treatment CS-8958, with Phase III trials set to commence later this year.
CS-8958 is a long-acting neuraminidase inhibitor [LANI], and is co-owned by Daiichi-Sankyo.
Several hundred flu patients participated in the double-blind trial, which was conducted to the standards of the Japanese Pharmaceuticals and Medical Devices Agency.
The trial revealed that one dose of CS-8958 produced results indistinguishable from 75mg of oseltamivir administered twice daily for five days.
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
